Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody.,Clinical & Translational Immunology

当前位置： X-MOL 学术 › Clin. Transl. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibody.
Clinical & Translational Immunology ( IF 5.8 ) Pub Date : 2020-07-15 , DOI: 10.1002/cti2.1156
Ziduo Li _{1,

2} , Edward Abadir _{1,

2,

3} , Kenneth Lee _{2,

4} , Candice Clarke ₄ , Christian E Bryant ₃ , Wendy Cooper ₃ , Geoffrey Pietersz _{5,

6} , James Favaloro ₃ , Pablo A Silveira _{1,

2} , Derek Nj Hart _{1,

2} , Xinsheng Ju _{1,

2} , Georgina J Clark _{1,

2}

Affiliation

Effective antibody–drug conjugates (ADCs) provide potent targeted cancer therapies. CD83 is expressed on activated immune cells including B cells and is a therapeutic target for Hodgkin lymphoma. Our objective was to determine CD83 expression on non‐Hodgkin lymphoma (NHL) and its therapeutic potential to treat mantle cell lymphoma (MCL) which is currently an incurable NHL.

中文翻译：

用抗人 CD83 抗体靶向套细胞淋巴瘤中的 CD83。

有效的抗体-药物偶联物 (ADC) 可提供有效的靶向癌症治疗。CD83 在活化的免疫细胞（包括 B 细胞）上表达，是霍奇金淋巴瘤的治疗靶点。我们的目标是确定 CD83 在非霍奇金淋巴瘤 (NHL) 上的表达及其治疗目前无法治愈的 NHL 套细胞淋巴瘤 (MCL) 的治疗潜力。

更新日期：2020-07-15

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>